A dark horse in the photovoltaic sector has obtained a key 'license,' the leading innovator in pharmaceuticals has received another favorable development, while a semiconductor silicon wafer leader has unexpectedly faced a reduction in holdings by the National Integrated Circuit Industry Investment Fund...
On February 6, the National Integrated Circuit Fund of Huguang Silicon Industry announced plans to reduce its stake by no more than 3%. Aikosun Corporation signed a Patent Licensing Agreement with Maxeon, and Hengrui Pharma's HRS-4642 injection was included in the list of breakthrough treatments.
The following are selected after-hours announcements:
Shanghai Silicon Industry: National Integrated Circuit Fund Plans to Reduce Holdings by No More Than 3%
Shanghai Silicon Industry announced that the National Integrated Circuit Industry Investment Fund Co., Ltd. holds 512 million shares of the company, accounting for 15.49%. The plan is to reduce holdings through block trading or centralized bidding within three months after 15 trading days from the date of this announcement, with no more than 99,150,700 shares reduced, not exceeding 3% of the company’s total share capital. The reduction period will be from March 10, 2026, to June 9, 2026, and the price will be determined based on market prices. Previously, this shareholder had already reduced holdings by 54,943,500 shares (accounting for 1.66%) between January 7, 2026, and January 19, 2026, at a price range of RMB 22.55 to 23.54 per share.
Aikosun Corporation: Signing of Patent Licensing Agreement with Maxeon
Aikosun Corporation announced that it has signed a Patent Licensing Agreement with Maxeon. The company has obtained authorization for all BC cell and module patents owned solely or jointly by Maxeon in the past and those newly added within the next five years, excluding the United States. This agreement does not involve reciprocal licensing. The total patent licensing fee amounts to RMB 1.65 billion, which will be paid in installments over the next five years, with the first-year fee being RMB 250 million.
Hengrui Pharma: HRS-4642 Injection Included in the Breakthrough Therapy Designation List
Hengrui Pharma (600276.SH) announced that its self-developed HRS-4642 Injection has been included in the Breakthrough Therapy Designation List by the Center for Drug Evaluation of the National Medical Products Administration. The proposed indication is for first-line treatment of advanced or metastatic pancreatic cancer carrying the KRASG12D mutation, in combination with gemcitabine and nab-paclitaxel. This product is a liposomal formulation KRASG12D inhibitor that can specifically bind to KRASG12D, inhibit the phosphorylation of MEK and ERK proteins, and exert anti-tumor effects. To date, the cumulative R&D investment for related projects amounts to approximately 254 million yuan. Drug development is subject to uncertainties due to various factors, including technical, regulatory, and policy-related risks.
Kema Technology: Application for the issuance of convertible corporate bonds to unspecified investors approved
Kema Technology announced that on February 6, 2026, the Listing Review Committee of the Shenzhen Stock Exchange convened its sixth review meeting of 2026 to examine Kema Technology's application for the issuance of convertible corporate bonds to unspecified investors. Based on the results of the meeting, the company’s application for this issuance complies with the issuance requirements, listing conditions, and information disclosure standards.
Heshun Electric: Contract worth RMB 60.0045 million signed with Bohai Drilling Engineering Co., Ltd. under China National Petroleum Corporation
Heshun Electric announced that it signed a Mobile Energy Storage Power Supply Service Contract with Bohai Drilling Engineering Co., Ltd. under China National Petroleum Corporation. The contract involves providing power supply services to meet production needs at drilling operation sites. The service period starts from the date of signing until December 31, 2028. The estimated contract value is RMB 60.0045 million (excluding tax), with the final settlement based on actual verified work volume. A performance bond of RMB 500,000 is required.
Huafa Co., Ltd.: Huafa Group intends to subscribe for 3 billion yuan worth of A-share stocks issued by Huafa Co., Ltd. to specific investors.
Huafa Co., Ltd. announced that Huafa Group intends to subscribe in cash for A-share stocks issued by Huafa Co., Ltd. to specific investors. The effectiveness and completion of this issuance of A-share stocks to specific investors are subject to approval by the relevant state-owned asset regulatory authorities, review and approval by the shareholders' meeting of Huafa Co., Ltd., examination and approval by the Shanghai Stock Exchange, and obtaining consent for registration from the China Securities Regulatory Commission. As a result of subscribing to the A-share stocks issued by Huafa Co., Ltd. to specific investors, the acquirer will hold more than 30% of the issued shares of the listed company.
Silver Jubilee Technology: Senior Executives Plan to Reduce Shareholdings by No More Than 0.51%
Silver Joy Technology announced that Lin Dengcan, a director and general manager, along with other directors and senior executives, plans to collectively reduce their holdings by up to 2,427,000 shares within three months after 15 trading days from the announcement date, representing 0.51% of the company’s total share capital. The reduction is primarily driven by personal financial needs, with the price determined by market conditions. The shares subject to reduction were sourced from the company’s equity incentive plan or secondary market purchases. This reduction will not result in a change of control or affect the company’s ongoing operations. The company will disclose updates on the implementation of the reduction plan as required.
Hunan Development: Issuance of shares and cash payment for asset acquisition along with raising complementary funds approved
Hunan Development announced that the company plans to acquire 85% equity in Hunan Xiangtou Yuanling Gaotan Power Generation Co., Ltd., 90% equity in Hunan Xiangtou Tongwan Water Conservancy and Hydropower Development Co., Ltd., 90% equity in Hunan Xiangtou Qingshuitang Hydropower Development Co., Ltd., and 88% equity in Hunan Xinshao Xiaoxi Hydropower Development Co., Ltd. held by Hunan Energy Group Electric Power Investment Co., Ltd. through the issuance of shares and cash payments. Concurrently, it will issue shares to no more than 35 qualified specific investors to raise complementary funds. The M&A Restructuring Review Committee of the Shenzhen Stock Exchange convened its third M&A restructuring review meeting on February 6, 2026, to deliberate on the application for this transaction by the company. According to the announcement of the results of the third deliberation meeting of the Shenzhen Stock Exchange M&A Restructuring Review Committee in 2026, the outcome of this meeting was that this transaction meets the restructuring conditions and information disclosure requirements. This transaction still requires approval from the China Securities Regulatory Commission (CSRC), and whether such approval can ultimately be obtained, as well as the exact timing, remains uncertain.
Dajia Weikang: Shareholder Changsha Tongjia plans to reduce holdings by no more than 3%.
Dajia Weikang announced that Changsha Tongjia Investment Management Partnership (Limited Partnership), a party acting in concert with controlling shareholder and actual controller Wang Yiqing, holds 9.8 million shares of the company, accounting for 4.77%. It plans to reduce holdings by no more than 6.1621 million shares, representing no more than 3.00%, through centralized bidding and block trading from March 10, 2026, to June 9, 2026, starting 15 trading days after the disclosure of this announcement. Within any consecutive 90 calendar days, centralized bidding will not exceed 1%, and block trading will not exceed 2%. The selling price will be no lower than the adjusted issue price.
China Merchants Shekou: The cash dividend ratio to net profit for the years 2026-2028 will be no less than 40%.
China Merchants Shekou announced that, in order to effectively enhance the company's investment value and strengthen returns to investors, the board of directors has reviewed and formulated a valuation enhancement plan. The specific measures include: deepening business focus to improve development quality; strengthening risk prevention and control, comprehensively building a 'fortress-like' balance sheet and a 'quilt-like' cash flow statement; enhancing value realization, increasing investor returns, and distributing cash dividends annually in principle. The cash dividend payout ratio for fiscal years 2026 to 2028 will be no less than 40% of net profits attributable to shareholders of the listed company.
Yuhuilong: The company has been investigated for suspected violations of information disclosure regulations.
Yuhuilong announced that it received a Notice of Investigation from the China Securities Regulatory Commission (CSRC) on February 6, 2026, due to suspected violations of information disclosure regulations. The CSRC has decided to initiate an investigation into the company.
Piano: The transfer of 9.78% of the company's shares by controlling shareholder Ma Libin has been completed.
Piano announced that the controlling shareholder and actual controller, Ma Libin, has completed the registration of the transfer of 17,888,400 shares (accounting for 9.78% of the total share capital) to Chuxinwei through a contractual agreement at a price of 15.31 yuan per share. After the transfer, Ma Libin’s shareholding ratio decreased to 29.34%, while Chuxinwei’s shareholding ratio increased to 16.78%. This transfer will not result in a change of the company’s controlling shareholder or actual controller.
Sanwei Xin'an: Plans to use its own funds of RMB 10 million to establish a wholly-owned subsidiary in the Hainan Free Trade Zone.
Sanwei Xin'an announced that at the 21st meeting of the second board of directors held on February 6, 2026, the proposal for establishing a wholly-owned subsidiary in Hainan was reviewed and approved. To meet the needs of the company’s future strategic development, it plans to use its own funds of RMB 10 million to establish a wholly-owned subsidiary in the Hainan Free Trade Zone.
Tiancheng New Materials: Under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure regulations.
Tiansheng New Materials announced that it received a Notice of Investigation (Reference No.: CSRC Investigation [2026] 0102026008) from the China Securities Regulatory Commission (CSRC) on February 6, 2026, due to suspected violations of information disclosure regulations. In accordance with relevant laws such as the Securities Law of the People’s Republic of China and the Administrative Punishment Law of the People’s Republic of China, the CSRC has decided to investigate the company. An internal review suggests this investigation may involve undisclosed related-party transactions from the 2023 fiscal year.
Lushan New Material: Controlling shareholder Wang Jiasheng and acting-in-concert party Lushan Information plan to collectively reduce holdings by no more than 3%.
Lushan New Materials announced that Wang Jiasheng, the controlling shareholder and actual controller, along with the acting-in-concert party Guangzhou Lushan Information Consulting Co., Ltd., plans to reduce their holdings by no more than 4,848,986 shares, representing 3% of the company’s total share capital.
Zhenyu Technology: Plans to establish a wholly-owned subsidiary in Thailand through its existing wholly-owned subsidiaries to invest in and construct a production and manufacturing base project in Thailand, with a total investment not exceeding 1.5 billion US dollars.
Zhenyu Technology announced that, in order to better meet the development needs of its emerging businesses and achieve the extension and expansion of its existing industrial chain, the company plans to establish a wholly-owned subsidiary in Thailand named Zhenyu Technology (Thailand) Co., Ltd., through its wholly-owned subsidiaries Zhenyu Technology (Hong Kong) Co., Ltd. and Zhenyu Technology Singapore Co., Ltd. This subsidiary will serve as the implementing entity for investing in and constructing a production and manufacturing base project in Thailand. The total investment will not exceed 1.5 billion US dollars, and the project will be constructed in phases. The planned total investment for Phase I will not exceed 750 million US dollars. After the completion of Phase I, subsequent phases will be advanced according to market conditions, corporate strategy, and financial arrangements.
Dalian Electric Porcelain: Estimated winning bid amount approximately RMB 119 million
Dalian Electric Porcelain announced that its wholly-owned subsidiary, Daci Materials, has been recommended as the winning bidder for the 66th batch of procurement by State Grid Corporation of China in 2025 (the fifth material tender procurement for UHV projects) and the first public tender procurement of equipment materials for power transmission and transformation projects in 2026. Daci Materials is expected to win bids for more than 187,000 pieces and over 95,000 pieces of porcelain insulators, as well as over 43,000 composite insulators. The total pre-winning bid amount is approximately RMB 119 million, accounting for 7.95% of the company’s audited operating revenue in 2024.
Sanfu Co., Ltd.: Plans to invest in the construction of a 200-ton-per-year (Phase I: 40 tons per year) SOD and supporting solvent project.
Sanfu Co., Ltd. announced that it plans to construct a project with an annual capacity of 200 tons (Phase I: 40 tons/year) of SOD and supporting solvents through its wholly-owned subsidiary, Tangshan Sanfu Electronic Materials Co., Ltd. The project will be implemented in two phases, with Phase I estimated to cost RMB 124.87 million and Phase II estimated to cost RMB 28.82 million.
Tanaka Seiki: Eight creditors of its former subsidiary, Youfu Intelligent Equipment, have jointly filed a lawsuit against the company, involving an amount of 108 million yuan.
Tanaka Seiki announced that on February 5, 2026, the company received a 'Civil Complaint' from the bankruptcy liquidation administrator of its former subsidiary, Shenzhen Youfu Intelligent Equipment Co., Ltd. Eight creditors of Youfu Intelligent jointly filed a lawsuit against the company. The plaintiffs are all creditors of Youfu Intelligent, and the defendant is the majority shareholder of Youfu Intelligent, holding 70% of its equity. The main reason for the plaintiffs’ objection is that the 'loan' provided by the defendant to Youfu Intelligent was in fact a capital contribution, which should not accrue interest, cannot be classified as a general creditor claim, and should rank behind ordinary creditor claims in terms of repayment priority.
Jinghe Integration: Plans to Acquire 100% Equity of Jingyi Integration for 2 Billion Yuan
Jinghe Integration announced that the company plans to invest RMB 2 billion in Hefei Jingyi Integrated Circuit Co., Ltd. through equity transfer and capital increase, acquiring 100% of its shares and consolidating it into the company's financial statements. This investment has been approved at the 30th meeting of the second board of directors and does not require submission to the shareholders' meeting for review. After the completion of the investment, Jingyi Integration will become a wholly-owned subsidiary of the company.
Tianshan Co., Ltd.: Planned net increase in short-term bond issuance for 2026 not to exceed 5 billion yuan
On February 6, Tianshan Co., Ltd. announced that the company and its subsidiaries plan to issue a net increase in short-term bonds not exceeding 5 billion yuan and medium- to long-term bonds not exceeding 14.1 billion yuan in 2026. The proceeds are intended to repay interest-bearing debt and supplement the company’s working capital.
Cuihua Jewelry: Subsidiary defaults on additional RMB 20 million loan
Cuihua Jewelry announced that its subsidiary, Shenzhen Cuihua Jewelry Co., Ltd. (referred to as “Shenzhen Cuihua”), due to tight working capital, failed to repay some loans as scheduled. As of the date of the announcement, Shenzhen Cuihua has defaulted on an additional loan with an outstanding principal of RMB 20 million. As of the date of the announcement, the total overdue principal of loans for the company and its subsidiaries amounts to RMB 254 million. To address the current debt issues properly, the company is maintaining close communication with relevant creditors and strives to gradually resolve the overdue debts through feasible solutions such as extensions and repayment plan adjustments.
ZTE Corporation: Plans to invest 200 million yuan to subscribe to the Guangdong-Hong Kong-Macao Fund
ZTE Corporation announced that it plans to act as a limited partner and invest 200 million yuan to subscribe to the shares of the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund Partnership (Limited Partnership), and sign the 'Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund Partnership (Limited Partnership) Agreement'.
Sunwoda: Subsidiary reaches settlement with Weirui Electric, expected to impact consolidated net profit for 2025 by RMB 500 million to RMB 800 million
Sunwoda announced that its subsidiary, Sunwoda Power (the defendant), reached a settlement with Weirui Electric (the plaintiff) during the first trial and signed a Settlement Agreement. The plaintiff will withdraw the lawsuit after the Settlement Agreement takes effect. The amount claimed by the plaintiff in this case was RMB 2.314 billion. According to the terms of the Settlement Agreement, both parties agreed to recognize costs based on actual expenses. Considering the warranty provisions already accrued by the company, the recoverable value of the relevant battery packs after the incident, and potential subsequent related expenses, the estimated impact on the company’s net profit attributable to shareholders for 2025 is between RMB 500 million and RMB 800 million.
Wan Tong Expressway: Plans to invest 5.42 billion yuan in the reconstruction and expansion project of Anhui section of G30 Lianhuo Expressway
Wan Tong Expressway announced that the company plans to invest approximately 5.42 billion yuan in the reconstruction and expansion project of the Anhui section of G30 Lianyungang–Khorgas Expressway. Among this, the capital fund will be about 1.084 billion yuan, accounting for 20% of the total investment, while the remaining 4.336 billion yuan will be financed through bank loans and other means. The project is expected to commence construction in 2026 and open to traffic by 2029. This project aims to improve road efficiency and service levels, enhance the company's competitiveness within the road network, promote high-quality economic and social development in the regions along the route, and support the healthy and sustainable development of the company. Meanwhile, the announcement also highlighted potential risks including policy risks, operational risks, and interest rate risks.
Zhongguancun: Signed the 'Traditional Chinese Medicine and Active Pharmaceutical Ingredients Base Construction Project Framework Agreement' with the Huachuan County Government
According to an announcement by Zhongguancun, the company signed the 'Traditional Chinese Medicine and Active Pharmaceutical Ingredients Base Construction Project Framework Agreement' with the People's Government of Huachuan County, Jiamusi City, Heilongjiang Province, on February 6, 2026, in Beijing. In line with the national 'Big Health' industrial development strategy, the company aims to enhance its production capacity in the traditional Chinese medicine and active pharmaceutical ingredients sectors and further strengthen its core competitiveness. It plans to build a modern digital factory in Huachuan County, Jiamusi City, Heilongjiang Province, to create a leading manufacturing base for traditional Chinese medicine and active pharmaceutical ingredients. The main source of funding will be the company’s own resources.
Tasly: Signs termination agreement to reclaim exclusive sales rights of T89 in the United States
Tasly announced that the company signed a Licensing Agreement with Arbor Pharmaceuticals, LLC of the United States in 2018, granting Arbor exclusive sales rights for Compound Danshen Dropping Pills in the U.S. Due to Arbor being acquired by Azurity Pharmaceuticals and undergoing business restructuring, both parties decided to terminate the cooperation and signed a Termination Agreement. According to the agreement, Tasly ultimately received a payment of USD 7.5 million. The termination of this cooperation will not have a significant impact on the company and does not harm the interests of the company or its shareholders.
Dongrui Co., Ltd.: January swine revenue totals RMB 214 million, up 25.19% month-over-month
According to an announcement by Dongrui Co., Ltd., in January 2026, the company sold a total of 162,800 pigs, generating sales revenue of 214 million yuan, marking a month-on-month increase of 25.19%. The average selling price of commercial pigs was 13.33 yuan per kilogram, up 6.30% month-on-month. Of this, 800 pigs were sold to its wholly-owned subsidiary, Heyuan Dongrui Meat and Food Co., Ltd.
Taiji Group: Plans to acquire 100% equity of Tongjunge Pharmaceutical Wholesale for RMB 23.43 million
Taiji Group announced that the company plans to acquire 90% of Chongqing Tongjun Pavilion Chinese Medicine Wholesale Co., Ltd. held by Chongqing Chinese Herbal Medicine Co., Ltd. for RMB 21.08 million in cash, and 10% of Tongjun Pavilion Chinese Medicine Wholesale held by Taiji Group Chongqing Fuling Pharmaceutical Co., Ltd. for RMB 2.35 million in cash. This equity transfer is conducted between the company and its holding subsidiaries, without involving external shareholders, and will not lead to changes in the scope of the company's consolidated financial statements or have an adverse impact on the company’s financial and operational status.
CICC: Plans to Issue $1.4 Billion Floating-Rate Notes for Debt Repayment and Other Purposes
CICC announced that on February 5, the company entered into a subscription agreement for the issuance of notes under its $10 billion guaranteed medium-term note program. The company will issue $550 million in floating-rate notes maturing in 2028 and $850 million in floating-rate notes maturing in 2029, both at 100% of the principal amount. The interest rates are set at SOFR compounded index + 0.48% per annum and SOFR compounded index + 0.53% per annum, respectively. The net proceeds will be used to repay part of the existing debt and for other general corporate purposes. An application has been made for the listing of the notes, which is expected to take effect on February 13. The notes have been rated 'Baa1' by Moody's.
Tianbang Foods: January commercial hog sales revenue reached RMB 674 million, a year-on-year increase of 9.93%.
Tianbang Foods announced that the company sold 682,000 commercial hogs in January 2026, generating sales revenue of RMB 674 million, with an average selling price of RMB 13.6 per kilogram (average price for commercial fattened hogs was RMB 12.5 per kilogram). The month-on-month changes were 2.97%, 10.01%, and 14.54%, respectively; year-on-year changes were 55.99%, 9.93%, and -17.83%, respectively.
Deppon Express: Plans to voluntarily withdraw from A-share listing; shares enter cash option declaration period.
Deppon Express announced that the company intends to voluntarily withdraw its A-share listing on the Shanghai Stock Exchange through a shareholder resolution and apply to enter the delisting board of the National Equities Exchange and Quotations System for small and medium-sized enterprises. This matter has been approved at the first extraordinary shareholders' meeting of 2026 and is still subject to the decision of the Shanghai Stock Exchange. Trading of the company's shares has been suspended since the market opening on January 21, 2026. The cash option declaration period is from February 9 to 12, during 9:30-11:30 and 13:00-15:00, with the declaration abbreviation and code being 'Deppon Cash, 770004.' Whether this delisting can be approved and implemented remains uncertain.
New Hope: 1.1218 million commercial hogs sold in January, a year-on-year increase of 9.70%.
New Hope announced that the company sold 1.1218 million commercial hogs in January 2026, representing a month-on-month change of -28.02% and a year-on-year change of 9.70%. The revenue from commercial hog sales was RMB 1.628 billion, with a month-on-month change of -20.15% and a year-on-year change of -10.03%. The average selling price of commercial hogs was RMB 12.48 per kilogram, with a month-on-month change of 10.64% and a year-on-year change of -19.01%.
Red Sun Pharmaceutical: Approval Received for Clinical Trial of Mesilate Nafamostat Injection
Red Sun Pharma announced that the company recently received a clinical trial approval notice from the National Medical Products Administration. According to the 'Pharmaceutical Administration Law of the People’s Republic of China' and relevant regulations, after review by the National Medical Products Administration, the company's application for the injection of Nafamostat Mesylate meets the relevant requirements for drug registration, and approval has been granted to conduct clinical trials for this product. The injection of Nafamostat Mesylate is used to improve acute symptoms of pancreatitis, treat disseminated intravascular coagulation syndrome, and prevent blood clotting during extracorporeal circulation in patients with bleeding disorders or a tendency to bleed.
Lisheng Pharmaceutical: Adenine Phosphate API Passes Market Application
Lisheng Pharmaceutical announced that the company has received the 'Approval Notice for Chemical API Market Application' issued by the National Medical Products Administration for Adenine Phosphate API, indicating that this product has passed the market application review for chemical APIs. Adenine Phosphate, formerly known as Vitamin B4, is a component of nucleic acids and coenzymes and participates in the synthesis of DNA and RNA in the body. It is an essential component for maintaining metabolic functions in living organisms. Clinically, it is used to prevent and treat leukopenia caused by various reasons, including acute granulocytopenia, particularly leukopenia induced by tumor chemotherapy and radiotherapy, as well as benzene poisoning.
Xuji Electric: Director Xu Tao Resigns
Xuji Electric announced that on February 6, 2026, the company received a written resignation report submitted by Mr. Xu Tao. Due to a work transfer, Mr. Xu Tao has tendered his resignation from the positions of director and member of the board's special committees. After stepping down from the aforementioned roles, Mr. Xu Tao will no longer hold any position within the company. As of the date of this announcement, Mr. Xu Tao does not hold any shares in the company, and his resignation has not resulted in the number of board members falling below the statutory requirement. According to relevant provisions of the Company Law and the Articles of Association, the resignation report takes effect from the date it was delivered to the company.
Zhenghong Technology: Sold 14,200 pigs in January, generating revenue of 14.3468 million yuan.
Zhenghong Technology announced that in January 2026, the company sold 14,200 pigs, generating revenue of 14.3468 million yuan, with month-over-month changes increasing by 431.21% and 940.76%, respectively. Year-over-year changes increased by 87.43% and 7.74%, respectively.
*ST Yuanshang: Extension Request for Response to the Shanghai Stock Exchange's Inquiry Letter on 2025 Earnings Forecast
*ST Yuanshang announced that the company received an inquiry letter from the Shanghai Stock Exchange on January 30, 2026, regarding its 2025 earnings forecast. The inquiry letter requested that the company disclose its response within five trading days of receipt. Given that the issues raised in the inquiry letter require further verification and supplementation, and need opinions from the annual audit accounting firm, to ensure accuracy and completeness of the response, the company has applied to the Shanghai Stock Exchange for a five-trading-day extension to respond.
Tianyu Bio: In January, the company sold 45,500 heads of live pigs, generating revenue of RMB 54.29 million.
Tianyu Bio announced that in January 2026, the company sold 45,500 heads of live pigs, generating revenue of RMB 54.29 million. The month-on-month changes were 16.10% and 21.49%, respectively, while the year-on-year changes were 15.58% and -11.23%, respectively. As of the end of January 2026, the company had an inventory of 211,000 heads of live pigs, representing a year-on-year increase of 24.07% and a month-on-month increase of 3.31%.
Wanma Co., Ltd.: Reorganizing 'Zhejiang Wanma Transmission Technology Co., Ltd.' into the Military Cable Project Department
Wanma Co., Ltd. announced that it will adjust its organizational structure. The company will establish the Party Affairs Department, Risk Control and Legal Review Center, Operations Management Center, Financial Management Center, Capital Operations Center, Supply Chain Management Center, Manufacturing Management Center, Research and Development Management Center, General Management Department, Engineering Management Department, and Safety and Environmental Protection Department. In addition, to improve the efficiency of resource utilization and promote the cultivation and development of emerging businesses, 'Zhejiang Wanma Transmission Technology Co., Ltd.' will be reorganized into the Military Cable Project Department and incorporated into the Equipment Cable Division for unified management.
